SGEN Misses Low Expectations, Shares Could Continue to Decline

Seattle Genetics (NASDAQ:SGEN) missed earnings expectations again, leaving analysts and investors uncertain about the company’s 2012 revenue guidance and beyond. Major shareholders may seek to trim positions, and some, like Wellington Management and Baker Brothers Life Sciences, already have as SGEN’s $2.8 billion valuation is being questioned given the rapidly flattening growth of the company’s cancer treatment and key value driver Adcetris. (more…)